Of these five drugs, tafenoquine succinate (a FDA-approved antimalarial drug targeting CYC1) and branaplam (a Phase 3 clinical trial drug targeting SMN1 for the treatment of spinal muscular atrophy) have not been reported as being associated with hepatocellular carcinoma [22–24]. This evidence concerns the gene CYC1 and spinal muscular atrophy.